IP Verse

Early Intervention Methods To Prevent Or Ameliorate Toxicity - EP3433276

The patent EP3433276 was granted to Seattle Childrens Hospital DBA Seattle Childrens Research Institute on Dec 22, 2021. The application was originally filed on Mar 22, 2017 under application number EP17719044A. The patent is currently recorded with a legal status of "Revoked".

EP3433276

SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RESEARCH INSTITUTE
Application Number
EP17719044A
Filing Date
Mar 22, 2017
Status
Revoked
Jun 13, 2025
Grant Date
Dec 22, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTSep 22, 2022BOULT WADE TENNANTADMISSIBLE
GILL JENNINGS & EVERYSep 22, 2022GILL JENNINGS & EVERYADMISSIBLE
PATENT BOUTIQUESep 22, 2022-ADMISSIBLE
GEDEON RICHTER PHARMASep 20, 2022MAIWALDADMISSIBLE

Patent Citations (61) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO1991US08442-
DESCRIPTIONWO1994US05601-
DESCRIPTIONEP0452342
DESCRIPTIONEP2537416
DESCRIPTIONUS2002131960
DESCRIPTIONUS2003170238
DESCRIPTIONUS2011003380
DESCRIPTIONUS2013149337
DESCRIPTIONUS2013287748
DESCRIPTIONUS2014271635
DESCRIPTIONUS265209
DESCRIPTIONUS4235871
DESCRIPTIONUS4452773
DESCRIPTIONUS4501728
DESCRIPTIONUS4690915
DESCRIPTIONUS4795698
DESCRIPTIONUS4837028
DESCRIPTIONUS5019369
DESCRIPTIONUS5087616
DESCRIPTIONUS5200084
DESCRIPTIONUS5219740
DESCRIPTIONUS5591827
DESCRIPTIONUS6040177
DESCRIPTIONUS6207453
DESCRIPTIONUS6410319
DESCRIPTIONUS6451995
DESCRIPTIONUS7070995
DESCRIPTIONUS7354762
DESCRIPTIONUS7446179
DESCRIPTIONUS7446190
DESCRIPTIONUS7446191
DESCRIPTIONUS8252592
DESCRIPTIONUS8324353
DESCRIPTIONUS8339645
DESCRIPTIONUS8389282
DESCRIPTIONUS8398282
DESCRIPTIONUS8479118
DESCRIPTIONUS8562991
DESCRIPTIONUS8802374
DESCRIPTIONUS8822647
DESCRIPTIONUS8911993
DESCRIPTIONWO0014257
DESCRIPTIONWO2009072003
DESCRIPTIONWO2010033140
DESCRIPTIONWO2012129514
DESCRIPTIONWO2013071154
DESCRIPTIONWO2013123061
DESCRIPTIONWO2013126726
DESCRIPTIONWO2013166321
DESCRIPTIONWO2014031687
DESCRIPTIONWO2014055668
INTERNATIONAL-SEARCH-REPORTWO2014011984
INTERNATIONAL-SEARCH-REPORTWO2016132366
INTERNATIONAL-SEARCH-REPORTWO2017035362
OPPOSITIONUS201662311906
OPPOSITIONUS201662417287
OPPOSITIONUS201662429722
OPPOSITIONWO2014011984
OPPOSITIONWO2017040930
OPPOSITIONWO2017165571
OPPOSITIONWO2018013918

Non-Patent Literature (NPL) Citations (54) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Allan R. Tunkel, "Fever - Infectious Diseases - MSD Manual Professional Edition", Internet Archive Wayback Machine, (20160224), pages 1 - 12, Internet Archive Wayback Machine, URL: https://web.archive.org/web/20160224024056/http://www.msdmanuals.com/professional/infectious-diseases/biology-of-infectious-disease/fever, (20221012), XP055970609-
OPPOSITION- Anandani Nellan, "Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques", Blood, (20180628), pages 662 - 666, Blood, URL: https://ashpublications.org/blood/article/132/6/662/39412/Improved-CNS-exposure-to-tocilizumab-after, (20201218), XP055761286-
OPPOSITION- Anonymous, "Actemra Prescribing Information", Actemra - reference ID:3393637, (20131000), pages 1 - 40, XP055972203-
OPPOSITION- Anonymous, "History of Changes for study: NCT020228455 A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 Leukemia", ClinicalTrials.gov archive, (20151230), ClinicalTrials.gov archive, (20221004), XP055967485-
OPPOSITION- Anonymous, "Historyof Changes for study: NCT02906371 Study of the Tocilizumab optimization Timing for CART19 Associated Cytokin release syndrome", clinicaltrials.gov, (20160928), clinicaltrials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT02906371?V2=View#StudyPageTop, (20221004), XP055967498-
OPPOSITION- Anonymous, "MINUTES OF RECOMBINANT DNA ADVISORY COMMITTEE'S (RAC) SYMPOSIUM", U.S. Department of Health and Human Services, (20150610), U.S. Department of Health and Human Services, URL: https://osp.od.nih.gov/wp-content/uploads/June 10 minutes.pdf, (20221004), XP055967479-
OPPOSITION- "Chapter 218: Temperature", Del Bene Victor E, Clinical Methods: The History, Physical, and Laboratory Examinations 3rd edition, (19900000), pages 990 - 993, XP055972194-
OPPOSITION- David T Teachey, S. F. Lacey, P. A. Shaw, J. J. Melenhorst, S. L. Maude, N. Frey, E. Pequignot, V. E. Gonzalez, F. Chen, J. Finklestein, D. M. Barrett, S. L. Weiss, J. C. Fitzgerald, R. A. Berg, R. Aplenc, C. Callahan, S. R. Rheingold, Z. Zheng, S. Rose-John, J. C. White, F. Nazimuddin, G. Wertheim, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, "Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia /Supplementary Material/", CANCER DISCOVERY, (20160601), pages 1 - 49, CANCER DISCOVERY, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406/, (20221012), XP055970620-
OPPOSITION- DR MICHAEL JENSEN, "CIPO2015: Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box", JENSEN LAB, (20150926), pages 1 - 39, XP055972165-
OPPOSITION- DR MICHAEL JENSEN et al., "Augmenting CAR T Cell Potency and Safety with Synthetic Control Systems", Jensen Lab, (20160401), pages 1 - 48, URL: https://www.nvas.org/ebriefings/sohn-conference-pediatric-cancer-in-a-post-genomic-world/?tab=media, XP055972216-
OPPOSITION- Elizabeth A. Martin (ed.), "fever (pyrexia)", Oxford - Concise Medical Dictionary, Oxford University Press, (20150101), page 284, ISBN 978-0-19-968781-7, XP009557734-
OPPOSITION- GARDNER et al., "Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy", Blood, (20190000), vol. 134, no. 24, pages 2149 - 2158, XP055967477-
OPPOSITION- Gardner, Et Al., "Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy", Blood, (20191212), vol. 134, no. 24, XP055967477-
OPPOSITION- Gardner Rebecca; Leger Kasey J; Annesley Colleen E; Summers Corinne; Rivers Julie; Gust Juliane; Tarlock Katherine; Cooper Todd M; Pinto Navin R; Finney Olivia; Smithers Hannah; Oron Assaf; Li Daniel; Park Julie R; Jensen Michael C, "Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management", Blood, American Society of Hematology, US, US , (20161202), vol. 128, no. 22, ISSN 0006-4971, page 586, XP009503769-
OPPOSITION- Gibney Michael, "Seattle Children's Pediatric Leukemia Adoptive therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia", PR Newswire Seattle Children, Seattle, Seattle, (20150421), PR Newswire Seattle Children, (20221004), XP055967492-
OPPOSITION- Harvey Marcovitch, "Fever", Harvey Marcovitch, Harvey Marcovitch, Black's Medical Dictionary, 41st Edition, A & C Black Publishers Limited, (20050101), pages 270 - 271, ISBN 0-7136-6146-1, XP009557735-
OPPOSITION- Jensen Michael, "Augmenting CAR T Cell Potency and Safety with Synthetic Control Systems", Jensen Lab, Sohn, (20160101), Jensen Lab, XP093212005-
OPPOSITION- Jensen, Michael C. - UW Video, "CIPO2015: Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box", URL: https://www.youtube.com/watch?v=TDxZS9hG4yQ, XP093207801-
OPPOSITION- Office Of The Director, Nih, "RAC Meeting Special Workshop: Cytokine Release Syndrome after T Cell Immunotherapy Meeting", URL: https://videocast.nih.gov/watch=16420, XP093210921-
OPPOSITION- PETERSON, T. C., "Cytokine antagonists: Thalidomide and Pentoxifylline in Hansen's disease", Can J Infect Dis, (19950000), vol. 6, no. 1, pages 30 - 33, XP055972234-
OPPOSITION- Strell Carina; Sievers Anne; Bastian Philipp; Lang Kerstin; Niggemann Bernd; Zänker Kurt S; Entschladen Frank, "Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes", BMC Immunology, (20091208), vol. 10, no. 62, pages 1 - 15, XP021066245-
OPPOSITION- Grupp Stephan A., "Advances in T-cell therapy for ALL /NIH Author Manuscript/", Best Practice & Research Clinical Haematology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20140901), vol. 27, no. 3-4, doi:10.1016/j.beha.2014.10.014, ISSN 1521-6926, pages 222 - 228, XP055970588
OPPOSITION- Xu Xiao-Jun; Tang Yong-Min, "Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells", Cancer Letters, (20140228), vol. 343, no. 2, pages 172 - 178, XP028814569
OPPOSITION- Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah, Seth M Steinberg, Dave Stroncek, Nick Tschernia, Constance Yuan, Hua Zhang, Ling Zhang, Steven A Rosenberg, Alan S Wayne, Crystal L Mackall, "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20150201), vol. 385, no. 9967, doi:10.1016/S0140-6736(14)61403-3, ISSN 0140-6736, pages 517 - 528, XP055388598
OPPOSITION- Jianshu Wei et al, "The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma", Signal Transduction and Targeted Therapy, (20201201), vol. 5, no. 1, doi:10.1038/s41392-020-00256-x, page 134, XP055761280
OPPOSITION- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy Morris Emma C; Neelapu Sattva S; Giavridis Theodoros; Sadelain Michel, "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy", Nature Reviews Immunology, (20210517), vol. 22, no. 2, pages 85 - 96, XP037682431
OPPOSITION- Stephan A. Grupp et al, "Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20130418), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, ISSN 0028-4793, pages 1509 - 1518, XP055169041
OPPOSITION- Shannon L. Maude, Noelle Frey, Pamela A. Shaw, Richard Aplenc, David M. Barrett, Nancy J. Bunin, Anne Chew, Vanessa E. Gonzalez, Zhaohui Zheng, Simon F. Lacey, Yolanda D. Mahnke, Jan J. Melenhorst, Susan R. Rheingold, Angela Shen, David T. Teachey, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp, "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia", New England Journal of Medicine, New England Journal of Medicine, (20141016), vol. 371, no. 16, doi:10.1056/NEJMoa1407222, ISSN 00284793, pages 1507 - 1517, XP055188099
OPPOSITION- S. Kang, T. Tanaka, T. Kishimoto, "Therapeutic uses of anti-interleukin-6 receptor antibody", International Immunology, Oxford University Press, GB, GB , (20150101), vol. 27, no. 1, doi:10.1093/intimm/dxu081, ISSN 0953-8178, pages 21 - 29, XP055377592
OPPOSITION- Nellan Anandani, Lee Daniel W., "Paving the road ahead for CD19 CAR T-cell therapy /HHS Author Manuscript/", CURRENT OPINION IN HEMATOLOGY, RAPID SCIENCE PUBLISHERS, PHILADELPHIA, PA., US, US , (20151101), vol. 22, no. 6, doi:10.1097/MOH.0000000000000182, ISSN 1065-6251, pages 516 - 520, XP055971005
OPPOSITION- NELLAN et al., "Paving the road ahead for CD19 CAR T-cell therapy", CURRENT OPINION IN HEMATOLOGY, (20151100), vol. 22, no. 6, pages 516 - 520, XP055971005
OPPOSITION- Barrett David M., Teachey David T., Grupp Stephan A., "Toxicity management for patients receiving novel T-cell engaging therapies /NIH Author Manuscript/", CURRENT OPINION IN PEDIATRICS., CURRENT SCIENCE, PHILADELPHIA, PA., US, US , (20140201), vol. 26, no. 1, doi:10.1097/MOP.0000000000000043, ISSN 1040-8703, pages 43 - 49, XP055970592
OPPOSITION- Maude Shannon L., Barrett David, Teachey David T., Grupp Stephan A., "Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, US , (20140301), vol. 20, no. 2, doi:10.1097/PPO.0000000000000035, ISSN 1528-9117, pages 119 - 122, XP055970614
OPPOSITION- Marco L. Davila, Craig Sauter, Renier Brentjens, "CD19-Targeted T Cells for Hematologic Malignancies : Clinical Experience to Date", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, US , (20150101), vol. 21, no. 6, doi:10.1097/PPO.0000000000000153, ISSN 1528-9117, pages 470 - 474, XP055377589
OPPOSITION- R. J. Brentjens, M. L. Davila, I. Riviere, J. Park, X. Wang, L. G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, O. Borquez-Ojeda, J. Qu, T. Wasielewska, Q. He, Y. Bernal, I. V. Rijo, C. Hedvat, R. Kobos, K. Curran, P. Steinherz, J. Jurcic, T. Rosenblat, P. Maslak, M. Frattini, M. Sadelain, "CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia", SCIENCE TRANSLATIONAL MEDICINE, (20130320), vol. 5, no. 177, doi:10.1126/scitranslmed.3005930, ISSN 1946-6234, pages 177ra38 - 177ra38, XP055234457
OPPOSITION- Davila M L; Riviere I; Wang X; Bartido S; Park J; Curran K; Chung S S; Stefanski J; Borquez-Ojeda O; Olszewska M; Qu J; Wasielewska T; He Q; Fink M; Shinglot H; Youssif M; Satter M; Wang Y; Hosey J; Quintanilla H; Halton E; Bernal Y; Bouhassira D C G; Arcila M E; Gonen M; Roboz G J; Maslak P; Douer D; Frattini M G; Giralt S; Sadelain M; Brentjens R, "Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia", SCIENCE TRANSLATIONAL MEDICINE, (20140219), vol. 6, no. 224, pages 1 - 12, XP055234425
OPPOSITION- M. L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, S. S. Chung, J. Stefanski, O. Borquez-Ojeda, M. Olszewska, J. Qu, T. Wasielewska, Q. He, M. Fink, H. Shinglot, M. Youssif, M. Satter, Y. Wang, J. Hosey, H. Quintanilla, E. Halton, Y. Bernal, D. C. G. Bouhassira, M. E. Arcila, M. Gonen, G. J. Roboz, P. Maslak, D. Douer, M. G. Frattini, S. Giralt, M. Sadelain, R. Brentjens, "Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia", SCIENCE TRANSLATIONAL MEDICINE, (20140219), vol. 6, no. 224, doi:10.1126/scitranslmed.3008226, ISSN 1946-6234, pages 224ra25 - 224ra25, XP055234366
OPPOSITION- D. T. Teachey, S. F. Lacey, P. A. Shaw, J. J. Melenhorst, S. L. Maude, N. Frey, E. Pequignot, V. E. Gonzalez, F. Chen, J. Finklestein, D. M. Barrett, S. L. Weiss, J. C. Fitzgerald, R. A. Berg, R. Aplenc, C. Callahan, S. R. Rheingold, Z. Zheng, S. Rose-John, J. C. White, F. Nazimuddin, G. Wertheim, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, "Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20160601), vol. 6, no. 6, doi:10.1158/2159-8290.CD-16-0040, ISSN 2159-8274, pages 664 - 679, XP055314472
OPPOSITION- Juliane Gust, Kevin A. Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F. Gonzalez-Cuyar, Cecilia Yeung, W. Conrad Liles, Mark Wurfel, Jose A. Lopez, Junmei Chen, Dominic Chung, Susanna Harju-Baker, Tahsin Özpolat, Kathleen R. Fink, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle, "Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20171201), vol. 7, no. 12, doi:10.1158/2159-8290.CD-17-0698, ISSN 2159-8274, pages 1404 - 1419, XP055590591
OPPOSITION- Brian C. Miller, Marcela V. Maus, "CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies", Oncology Research and Treatment, Karger, CH, CH , vol. 38, no. 12, doi:10.1159/000442170, ISSN 2296-5270, pages 683 - 690, XP055347437
OPPOSITION- TASIAN et al., "CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)", Therapeutic Advances in Hematology, (20150706), vol. 6, no. 5, pages 228 - 241, XP055406974
OPPOSITION- Frey Noelle V; Porter David L, "Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.", HEMATOLOGY / THE EDUCATION PROGRAM OF THE AMERICAN SOCIETY OF HEMATOLOGY, American Society of Hematology, US, US , (20161202), vol. 2016, no. 1, doi:10.1182/asheducation-2016.1.567, ISSN 1520-4383, pages 567 - 572, XP008184859
OPPOSITION- D. T. Teachey, S. R. Rheingold, S. L. Maude, G. Zugmaier, D. M. Barrett, A. E. Seif, K. E. Nichols, E. K. Suppa, M. Kalos, R. A. Berg, J. C. Fitzgerald, R. Aplenc, L. Gore, S. A. Grupp, "Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy", Blood, (20130627), vol. 121, no. 26, doi:10.1182/blood-2013-02-485623, ISSN 00064971, pages 5154 - 5157, XP055188107
OPPOSITION- D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. Grupp, C. L. Mackall, "Current concepts in the diagnosis and management of cytokine release syndrome", Blood, American Society of Hematology, US, US , (20140710), vol. 124, no. 2, doi:10.1182/blood-2014-05-552729, ISSN 0006-4971, pages 188 - 195, XP055313556
OPPOSITION- Lee D W; Gardner R; Porter D L; Louis C U; Ahmed N; Jensen M; Grupp S A; Mackall C L, "Current concepts in the diagnosis and management of cytokine release syndrome", Blood, (20140710), vol. 124, no. 2, pages 188 - 195, XP055313556
OPPOSITION- Shannon L Maude; Teachey David T; Porter David L; Grupp Stephan A, "CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia", Blood, (20150521), vol. 125, no. 26, pages 4017 - 4023, XP055565639
OPPOSITION- Shannon L Maude, Teachey David T, Porter David L, Grupp Stephan A, "CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia", Blood, (20150625), vol. 125, no. 26, doi:10.1182/blood-2014-, pages 4017 - 4023, XP055565639
OPPOSITION- Jennifer N. Brudno, James N. Kochenderfer, "Toxicities of chimeric antigen receptor T cells: recognition and management", Blood, American Society of Hematology, US, US , (20160630), vol. 127, no. 26, doi:10.1182/blood-2016-04-703751, ISSN 0006-4971, pages 3321 - 3330, XP055442400
OPPOSITION- S. A. Ali, V. Shi, I. Maric, M. Wang, D. F. Stroncek, J. J. Rose, J. N. Brudno, M. Stetler-Stevenson, S. A. Feldman, B. G. Hansen, V. S. Fellowes, F. T. Hakim, R. E. Gress, J. N. Kochenderfer, "T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma", Blood, American Society of Hematology, US, US , (20160929), vol. 128, no. 13, doi:10.1182/blood-2016-04-711903, ISSN 0006-4971, pages 1688 - 1700, XP055334154
OPPOSITION- Rebecca A. Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen Spratt, Virginia Hoglund, Catherine Lindgren, Assaf P. Oron, Daniel Li, Stanley R. Riddell, Julie R. Park, Michael C. Jensen, "Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults", Blood, American Society of Hematology, US, US , (20170622), vol. 129, no. 25, doi:10.1182/blood-2017-02-769208, ISSN 0006-4971, pages 3322 - 3331, XP055509718
OPPOSITION- Marofi Faroogh; Motavalli Roza; Safonov Vladimir A; Thangavelu Lakshmi; Yumashev Alexei Valerievich; Alexander Markov; Shomali Navid; Chartrand Max Stanley; Pathak Yashwant; Jarahian Mostafa; Izadi Sepideh; Hassanzadeh Ali; Shirafkan Naghmeh; Tahmasebi Safa; Khiavi Farhad Motavalli, "CAR T cells in solid tumors: challenges and opportunities", Stem Cell Research & Therapy, (20210125), vol. 12, no. 81, pages 1 - 16, XP055971962
OPPOSITION- Marofi Faroogh, Rahman Heshu Sulaiman, Al-Obaidi Zaid Mahdi Jaber, Jalil Abduladheem Turki, Abdelbasset Walid Kamal, Suksatan Wanich, Dorofeev Aleksei Evgenievich, Shomali Navid, Chartrand Max Stanley, Pathak Yashwant, Hassanzadeh Ali, Baradaran Behzad, Ahmadi Majid, Saeedi Hossein, Tahmasebi Safa, Jarahian Mostafa, "Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients", Stem Cell Research & Therapy, (20211201), vol. 12, no. 1, doi:10.1186/s13287-021-02420-8, page 465, XP055970985
OPPOSITION- Le Robert Q., Li Liang, Yuan Weishi, Shord Stacy S., Nie Lei, Habtemariam Bahru A., Przepiorka Donna, Farrell Ann T., Pazdur Richard, "FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome", THE ONCOLOGIST, (20180801), vol. 23, no. 8, doi:10.1634/theoncologist.2018-0028, ISSN 1083-7159, pages 943 - 947, XP093212605
OPPOSITION- Jaina M Patel, Gordon A Dale, Vincent F Vartabedian, Paulami Dey, Periasamy Selvaraj, "Cancer CARtography: charting out a new approach to cancer immunotherapy", Immunotherapy, Future Medicine Ltd., GB, GB , (20140601), vol. 6, no. 6, doi:10.2217/imt.14.44, ISSN 1750-743X, pages 675 - 678, XP055188250

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents